Company Profiles

driven by the PitchBook Platform

Nuclea Biotechnologies

Description

Developer of clinical diagnostic tests designed to offer diagnostic developments in cancer, including colon, stomach, leukemia, lung and prostate cancer, as well as cardiovascular, neurological, inflammation and metabolic disorders. The company's clinical diagnostic tests offer a suite of highly sensitive, specific and selective proteomic tests uses innovate proprietary technology and mass spec testing capabilities that fuel growth across five major cancer types as well as metabolic disease, enabling doctors to make early detection and monitoring of prostate and breast cancer, diabetes and other metabolic syndromes within the oncology and endocrinology fields of medicine.

2005

Founded

OOB

Status

51-200

Employees

Liquidation

Latest Deal Type

$45.4M

Total Amount Raised

Description

Developer of clinical diagnostic tests designed to offer diagnostic developments in cancer, including colon, stomach, leukemia, lung and prostate cancer, as well as cardiovascular, neurological, inflammation and metabolic disorders. The company's clinical diagnostic tests offer a suite of highly sensitive, specific and selective proteomic tests uses innovate proprietary technology and mass spec testing capabilities that fuel growth across five major cancer types as well as metabolic disease, enabling doctors to make early detection and monitoring of prostate and breast cancer, diabetes and other metabolic syndromes within the oncology and endocrinology fields of medicine.

Website:

www.nucleabio.com

Ownership Status

Out of Business

Financing Status

Formerly VC-Backed

Primary Industry

Therapeutic Devices

Other Industries

Diagnostic Equipment

Primary Office

46-48 Elm Street Pittsfield, MA 01201United States +1 (617) 492-3900
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Nuclea Biotechnologies's full profile, request a free trial.

Nuclea Biotechnologies Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Nuclea Biotechnologies Executive Team (6)

NameTitleBoard
Seat
Contact
Info
Donald PogorzelskiPresident & Chief Executive Officer
Mary LopezChief Operating Officer & Vice President of Proteomics Discovery
Deborah August MDChief Pathologist and Medical Director
Sheryl Brown-ShimerVice President of Regulatory Affairs & Project Management & Senior Director Regulatory Affairs
Bryan KrastinsVice President of Business Development and CLIA Laboratory Operations
Donald Pogorzelski President & Chief Executive Officer
Mary Lopez Chief Operating Officer & Vice President of Proteomics Discovery
Deborah August MD Chief Pathologist and Medical Director
Sheryl Brown-Shimer Vice President of Regulatory Affairs & Project Management & Senior Director Regulatory Affairs
Bryan Krastins Vice President of Business Development and CLIA Laboratory Operations

Nuclea Biotechnologies Board Members (1)

NameRepresentingRoleSinceContact
Info
William HarmanSelfBoard Member000 0000
William Harman Board Member Self
Request full access to PitchBook